KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Co-Diagnostics (CODX) over the last 6 years, with Q3 2025 value amounting to -$43681.0.

  • Co-Diagnostics' Asset Writedowns and Impairment fell 15424.53% to -$43681.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $22574.0, marking a year-over-year decrease of 9922.03%. This contributed to the annual value of $326512.0 for FY2024, which is 8990.15% down from last year.
  • Co-Diagnostics' Asset Writedowns and Impairment amounted to -$43681.0 in Q3 2025, which was down 15424.53% from -$57981.0 recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Asset Writedowns and Impairment ranged from a high of $2.7 million in Q4 2023 and a low of -$86339.0 during Q4 2021
  • Over the past 5 years, Co-Diagnostics' median Asset Writedowns and Impairment value was $48702.0 (recorded in 2024), while the average stood at $313237.6.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 386616.08% in 2022, then tumbled by 26228.45% in 2025.
  • Co-Diagnostics' Asset Writedowns and Impairment (Quarter) stood at -$86339.0 in 2021, then soared by 2558.88% to $2.1 million in 2022, then rose by 28.6% to $2.7 million in 2023, then tumbled by 94.08% to $161557.0 in 2024, then tumbled by 127.04% to -$43681.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$43681.0 for Q3 2025, versus -$57981.0 for Q2 2025 and -$37321.0 for Q1 2025.